0 Ratings
ID

13094

Description

Beta-Cell Transplantation in Pre-Uremic Patients With Type 1 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT00623610

Link

https://clinicaltrials.gov/show/NCT00623610

Keywords

Versions (1)
  1. 1/15/16 1/15/16 -
Uploaded on

January 15, 2016

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

  • Newest
  • Oldest
  • Popular
  • Newest
    • Newest
    • Oldest
    • Popular

    No comments

    In order to download data models you must be logged in. Please log in or register for free.

    Eligibility Diabetes Mellitus, Type 1 NCT00623610

    English

    Eligibility Diabetes Mellitus, Type 1 NCT00623610

    1 forms  
    Inclusion Criteria
    Description

    Inclusion Criteria

    Alias
    UMLS CUI
    C1512693
    type 1 insulin-dependent diabetic patients in relatively good general condition
    Description

    type 1 diabetes, health status

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C0011854
    UMLS CUI [2]
    C0018759
    non-smoker
    Description

    tobacco use

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C0543414
    body weight < 80 kg
    Description

    weight

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C0005910
    c-peptide < 0.03 nmol/l (<0.09 µg/l) 6 min. after glucagon iv (1mg) (glycemia > 180 mg/dl)
    Description

    c-peptide after glucagon

    Data type

    boolean

    Alias
    UMLS CUI [1,1]
    C0202100
    UMLS CUI [1,2]
    C0332282
    UMLS CUI [1,3]
    C0017687
    ebv antibody positive
    Description

    ebv antibody positive

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C0241883
    cooperative and reliable patient giving informed consent by signature; the patient should be informed in sufficient detail on the content and procedure of the protocol, indicating potential risks of intervention and of immunosuppressive therapy; the patient should also be informed that withdrawal of immunosuppressive therapy in patients with persistent plasma c-peptide positivity may result in subsequent loss of ß-cell graft function; the ß cell implant should be identified as a clinical trial.
    Description

    informed consent, compliance

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C0021430
    UMLS CUI [2]
    C1321605
    Exclusion Criteria
    Description

    Exclusion Criteria

    Alias
    UMLS CUI
    C0680251
    history of thrombosis or pulmonary embolism
    Description

    thrombosis, pulmonary embolism

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C0040053
    UMLS CUI [2]
    C0034065
    abnormal liver function
    Description

    liver dysfunction

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C0086565
    hla antibodies
    Description

    hla antibodies

    Data type

    boolean

    Alias
    UMLS CUI [1]
    C0024284
    Back to the top of the page

    Similar models

    Eligibility Diabetes Mellitus, Type 1 NCT00623610

    1 forms
    Name
    Type
    Description | Question | Decode (Coded Value)
    Data type
    Alias
    Item Group
    C1512693 (UMLS CUI)
    type 1 diabetes, health status
    Item
    type 1 insulin-dependent diabetic patients in relatively good general condition
    boolean
    C0011854 (UMLS CUI [1])
    C0018759 (UMLS CUI [2])
    tobacco use
    Item
    non-smoker
    boolean
    C0543414 (UMLS CUI [1])
    weight
    Item
    body weight < 80 kg
    boolean
    C0005910 (UMLS CUI [1])
    c-peptide after glucagon
    Item
    c-peptide < 0.03 nmol/l (<0.09 µg/l) 6 min. after glucagon iv (1mg) (glycemia > 180 mg/dl)
    boolean
    C0202100 (UMLS CUI [1,1])
    C0332282 (UMLS CUI [1,2])
    C0017687 (UMLS CUI [1,3])
    ebv antibody positive
    Item
    ebv antibody positive
    boolean
    C0241883 (UMLS CUI [1])
    informed consent, compliance
    Item
    cooperative and reliable patient giving informed consent by signature; the patient should be informed in sufficient detail on the content and procedure of the protocol, indicating potential risks of intervention and of immunosuppressive therapy; the patient should also be informed that withdrawal of immunosuppressive therapy in patients with persistent plasma c-peptide positivity may result in subsequent loss of ß-cell graft function; the ß cell implant should be identified as a clinical trial.
    boolean
    C0021430 (UMLS CUI [1])
    C1321605 (UMLS CUI [2])
    Item Group
    C0680251 (UMLS CUI)
    thrombosis, pulmonary embolism
    Item
    history of thrombosis or pulmonary embolism
    boolean
    C0040053 (UMLS CUI [1])
    C0034065 (UMLS CUI [2])
    liver dysfunction
    Item
    abnormal liver function
    boolean
    C0086565 (UMLS CUI [1])
    hla antibodies
    Item
    hla antibodies
    boolean
    C0024284 (UMLS CUI [1])
    Back to the top of the page 

    Help

    Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

    Watch Tutorial